Globally, 2025 marked a shift from debating drug pricing policy to implementing it. Pricing pressure intensified, evidence expectations rose, and long-standing access models began to change amid political and fiscal realities. In Trinity’s webinar “Around the World in Market Access…
Across Europe, 2025 accelerated a shift from sequential regulatory and access steps to more connected process through the Joint Clinical Assessment. Regulatory approvals, and clinical portion of HTA evaluation are now more tightly linked, which has the potential to bring…
Latin American and MENA markets have long faced the challenge of balancing constrained public budgets with rising demand for newer therapies. In 2025, governments in these regions took concrete steps to modernize pricing rules, raise evidence expectations, expand partnership models,…
China is evolving beyond a single public reimbursement model toward a layered access system that combines national coverage, commercial funding, and early access programs. In 2025, these changes began to reshape how manufacturers think about pricing, evidence, and launch sequencing…